Longwood Fund
Venture capitalBoston · Series A–Series B · 21 people tracked
Investment thesis
Longwood Fund focuses on creating and investing in novel healthcare companies that develop important treatments. The firm combines deep company creation and operating experience with partnerships among world-class entrepreneurs, scientists, and academic innovators to identify groundbreaking discoveries. The team's founding track record includes over 20 biotech companies that have launched approximately 25 drugs and generated sustained market capitalizations exceeding $170 billion.
Source: firm website, verified Jul 21, 2026.
Team · 21 people
from the firm's websiteWhat they invest in
from 12 of 62 portfolio companiesBiotech ×12Medical Devices ×10Healthtech ×4AI & Machine Learning ×3Digital Health ×2Deep Tech ×1
HQs:United States×4Canada×1
Investments · showing 60 of 62
founders shown can be your intro pathCoultreon is a drug discovery and development company that advances small and large molecule therapeutic programmes across various disease areas, combining disease biology expertise with technology platforms.
AI & Machine LearningBiotech
Pierre Raboisson(Chief Executive Officer Chief Scientific Officer Co-founder)Marie De Vulder(Chief Legal Officer Co-founder)Guy Peeters(Chief Financial Officer Co-founder)John-Paul Gallivan(Head of Development Co-founder)
Flex Pharma provides accessible generic vasodilator medications, including PDE5 inhibitors, to U.S. patients at lower costs than brand-name alternatives. The company focuses on vessel health and blood flow optimization for applications ranging from athletic performance to sexual wellness.
BiotechDigital HealthHealthtechMedical Devices
Dr. Rod MacKinnon(Founder)
GRAIL develops the Galleri blood test for multi-cancer early detection using next-generation sequencing and machine learning to screen for multiple deadly cancer types before symptoms appear. The test is offered by prescription in the United States and through partnerships with healthcare systems, insurance carriers, and diagnostic platforms.
AI & Machine LearningBiotechHealthtechMedical DevicesMenlo Park, US
Joshua Ofman, MD, MSHS(Chief Executive Officer)
Immunitas discovers and develops therapeutic antibodies for cancer and autoimmune diseases, with its lead program targeting CD161 for solid tumors and hematological malignancies. The company is building on research from academic institutions including Dana Farber Cancer Institute and MIT.
BiotechDigital HealthMedical Devices
Mediartx develops novel therapies for patients with fibrotic diseases.
BiotechMedical Devices
Rahul Ballal, PhD(CEO)Paul Yaworsky, PhD(CSO)
Progentos develops small-molecule therapeutics to stimulate myelin regeneration in multiple sclerosis patients by activating oligodendrocyte progenitor cells. The company targets the significant unmet need for remyelinating treatments that could repair damage caused by MS and potentially restore lost function.
BiotechDeep TechMedical Devices
Verastem Oncology is a biopharmaceutical company that discovers and develops drugs to treat cancer patients. The company focuses on oncology therapeutics including small molecules and monoclonal antibodies targeting pathways such as RAS, KRAS, and immune modulation.
BiotechMedical Devices
Robert Weinberg
Werewolf Therapeutics is a biotechnology company developing immunotherapy treatments for cancer. The company focuses on leveraging immune modulation and innovative therapeutic approaches in oncology.
BiotechHealthtechMedical DevicesWatertown, US
Daniel J. Hicklin(Founder, President, Chief Executive Officer, and Board member)Luke Evnin(Co-founder, Board member (Chairman))
Avenzo Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic treatments. The company focuses on oncology and cell therapy programs.
Biotech
Athena Countouriotis(Co-Founder, Chief Executive Officer)
Sidewinder Bio develops next-generation bispecific antibody-drug conjugates (ADCs) designed to treat solid tumors with enhanced specificity for difficult-to-treat cancers. The company engineers therapies targeting receptor co-complexes to improve therapeutic window and tumor cell specificity.
BiotechMedical Devices
Frequently asked questions
- What stage does Longwood Fund invest at?
- Longwood Fund invests at the Series A, Series B stages.
- What sectors does Longwood Fund focus on?
- Longwood Fund focuses on Biotech, Healthtech, Medical Devices.
- Where is Longwood Fund located?
- Longwood Fund is headquartered in Boston, US.
Similar investors
B Capital is a venture capital firm managing over $12 billion in assets with a stage-based fund approach. The firm invests across early to late-stage companies in technology, healthcare, and energy & resilience sectors, with 200+ portfolio companies and 9 global offices.
Breyer Capital is a venture capital firm that invests in high-impact entrepreneurs with a strategic focus on companies leveraging artificial intelligence and machine learning to transform technology sectors globally.
DCVC is a deep tech venture capital firm with over a dozen years of experience backing entrepreneurs using computational approaches to solve trillion-dollar problems across industries including AI, climate, materials science, robotics, space, and biology.
GV is Alphabet's venture capital arm, established in 2009 as Google Ventures. Operating with long time horizons and over $13 billion in assets under management, the firm invests across technology and life sciences sectors from seed to growth stages, supporting 400 active portfolio companies across North America, Europe, and Israel.
Innovestor is a Finnish investment manager that operates across venture capital, real estate, and energy storage sectors. The firm invests in early-stage technology and life science startups, energy-efficient commercial real estate, and battery storage and solar solutions. Innovestor also provides corporate venturing advisory services.